TY - JOUR
T1 - Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment
AU - Chan, Clement K.
AU - Lin, S. G.
PY - 2007
Y1 - 2007
N2 - PURPOSE. To describe the unusual complication of retinal pigment epithelial (RPE) tear after intravitreal ranibizumab (Lucentis®) for subfoveal fibrovascular pigment epithelial detachment (PED) and its effective management. METHODS. Chart review for case report of RPE tear after ranibizumab. RESULTS. An inferior RPE tear was documented by fluorescein angiography, fundus photography, and optical coherence tomography (OCT) 1 month after receiving repeat ranibizumab injection in the right eye of a patient with bilateral subfoveal fibrovascular PED. He had undergone multiple bevacizumab followed by ranibizumab injections for neovascular age-related macular degeneration (AMD) in both eyes, starting 6 months previously. Subsequent antivascular endothelial growth factor (VEGF) therapy improved vision of right eye from 20/200 to 20/40, despite RPE tear. CONCLUSIONS. RPE tear may form after anti-VEGF therapy, including ranibizumab injection. Further anti-VEGF therapy may preserve or improve vision. To the authors' knowledge, this is first case report of effective suppression of neovascular activity with bevacizumab after an RPE tear following ranibizumab therapy.
AB - PURPOSE. To describe the unusual complication of retinal pigment epithelial (RPE) tear after intravitreal ranibizumab (Lucentis®) for subfoveal fibrovascular pigment epithelial detachment (PED) and its effective management. METHODS. Chart review for case report of RPE tear after ranibizumab. RESULTS. An inferior RPE tear was documented by fluorescein angiography, fundus photography, and optical coherence tomography (OCT) 1 month after receiving repeat ranibizumab injection in the right eye of a patient with bilateral subfoveal fibrovascular PED. He had undergone multiple bevacizumab followed by ranibizumab injections for neovascular age-related macular degeneration (AMD) in both eyes, starting 6 months previously. Subsequent antivascular endothelial growth factor (VEGF) therapy improved vision of right eye from 20/200 to 20/40, despite RPE tear. CONCLUSIONS. RPE tear may form after anti-VEGF therapy, including ranibizumab injection. Further anti-VEGF therapy may preserve or improve vision. To the authors' knowledge, this is first case report of effective suppression of neovascular activity with bevacizumab after an RPE tear following ranibizumab therapy.
KW - Bevacizumab
KW - Intravitreal injection
KW - Lucentis®
KW - Ranibizumab
KW - Retinal pigment epithelial rips
KW - Retinal pigment epithelial tears
UR - http://www.scopus.com/inward/record.url?scp=38449095942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38449095942&partnerID=8YFLogxK
U2 - 10.1177/112067210701700432
DO - 10.1177/112067210701700432
M3 - Article
C2 - 17671950
SN - 1120-6721
VL - 17
SP - 674
EP - 676
JO - European Journal of Ophthalmology
JF - European Journal of Ophthalmology
IS - 4
ER -